OTC: BOIRF - Boiron SA

Yield per half year: 0%
Dividend yield: +3.41%
Sector: Healthcare

Share chart Boiron SA


About Boiron SA

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy.

more details
It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета eur
Див.доход ао 3.41
Дивиденд ао 1.25
Сайт https://www.boiron.fr
Цена ао 35.85
Change price per day: 0% (35.85)
Change price per week: 0% (35.85)
Change price per month: 0% (35.85)
Change price per 3 month: 0% (35.85)
Change price per half year: 0% (35.85)
Change price per year: -2.61% (36.81)
Change price per year to date: 0% (35.85)

Underestimation

Title Value Grade
P/S 1.36 9
P/BV 1.71 8
P/E 18.69 7
EV/EBITDA 9.33 8
Total: 7.63

Efficiency

Title Value Grade
ROA, % 6.07 2
ROE, % 9.1 3
Total: 2.5

Dividends

Title Value Grade
Div yield, % 3.41 8.53
DSI 0.7143 7.14
Total: 5.82

Debt

Title Value Grade
Debt/EBITDA 0.1148 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -11.47 0
Yield Ebitda, % -40.88 0
Yield EPS, % -19.14 0
Total: 2



Head Job title Payment Year of birth
Mr. Jean-Christophe Bayssat Deputy GM, Chief Pharmacist & Director of Pharmaceutical Development 441.18k 1963 (62 years)
Mr. Eric Lambert Secretary General and Chief Financial & Administrative Officer N/A
Mr. Patrice Varraut Director of Operations N/A
Ms. Juliette Baudry Human Resources Director N/A
Fabrice Rey Group Treasurer N/A
Mr. Thierry Boiron GM & Director 1961 (64 years)

Address: France, Messimy, 2 avenue de l’Ouest Lyonnais - open in Google maps, open in Yandex maps
Website: https://www.boiron.fr